Brain-derived neurotrophic factor in neurodegenerative diseases

  title={Brain-derived neurotrophic factor in neurodegenerative diseases},
  author={Chiara Zuccato and Elena Cattaneo},
  journal={Nature Reviews Neurology},
Changes in the levels and activities of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), have been described in a number of neurodegenerative disorders, including Huntington disease, Alzheimer disease and Parkinson disease. It is only in Huntington disease, however, that gain-of-function and loss-of-function experiments have linked BDNF mechanistically with the underlying genetic defect. Altogether, these studies have led to the development of experimental strategies… 
Huntington's disease.
This chapter describes how huntingtin protein, whose mutation causes Huntington disease, is involved in the physiological control of BDNF synthesis and transport in neurons and how both processes are simultaneously disrupted in HD.
GDNF, NGF and BDNF as therapeutic options for neurodegeneration.
Brain-Derived Neurotrophic Factor and Stem Cell-Based Technologies in Huntington’s Disease Therapy
Neurodegenerative disorders, such as Huntington’s disease (HD), Alzheimer’s disease (AD), and Parkinson’s disease (PD), are characterized by changes in the levels and activities of neurotrophic
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy
E enlightening the detailed biological ability and complicated mechanisms of action of BDNF in the context of AD would provide a future BDNF-related remedy for AD, such as increment in the production or release of endogenous BDNF by some drugs or BDNF mimics.
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential
An overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling is presented and the potential of BDNF-targeting therapeutics for AD is discussed.
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Evidence is focused on the evidence that increasing BDNF level due to gene modulation or physical exercise has a neuroprotective effect and could be considered as adjunctive therapy in PD.
Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease
Levels of BDNF in human blood were not informative (mRNA levels or plasma protein level) nor reliable (serum protein levels) as HD biomarkers, and the scientific community is warned in interpreting the significance of changes measured in BDNF protein levels in serum from patients suffering from different conditions.
New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases.
This review revisits the gene structure, transcription, translation, transport and secretion mechanisms of BDNF, and introduces implications ofBDNF in several brain-related diseases including Alzheimer's disease, Huntington’s disease, depression and schizophrenia.
BDNF in the Aged Brain: Translational Implications for Parkinson's Disease.
The extent of the existing literature on age-related BDNF changes is summarized, and the relevance of these changes as a factor potentially impacting therapeutics in aged parkinsonian subjects is discussed.


The expanding role of BDNF: a therapeutic target for Alzheimer's disease?
It appears clear that BDNF is implicated in the mechanism of action of drugs that improve cognitive deficits in animal models of AD and in AD patients, and this review will focus on different pharmacological interventions currently in use or drugs under development that interfere with the expression of the trophic factor brain-derived neurotrophic factor.
Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease
The mechanism of action of established as well as novel drugs for PD is discussed with a particular emphasis to those interfering with BDNF biosynthesis, as its enhanced expression ameliorates cognitive processes.
Brain‐derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer's disease in Italy
The data suggest that BDNF genetic variants are not a susceptibility factor for AD, nor do they mitigate the effect of ApoE ε4 allele on AD risk.
Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease
It is demonstrated that the downregulation of BDNF by mutant Huntingtin depends on the length and levels of expression of the CAG repeats in cell cultures, and it is shown that the deficit of endogenous BDNF modulates the pathology of Huntington's disease.
Brain-derived neurotrophic factor.
Since the purification of BDNF in 1982, a great deal of evidence has mounted for its central roles in brain development, physiology, and pathology, and application of the trophic properties ofBDNF may lead to novel therapeutic options in neurodegenerative diseases and perhaps even in neuropsychiatric disorders.
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
It is demonstrated that wild-type huntingtin up-regulates transcription of brain-derived neurotrophic factor (BDNF), a pro-survival factor produced by cortical neurons that is necessary for survival of striatal neurons in the brain.
Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration
A testable model of HD pathogenesis is presented that begins to account for regional specificity in human HD and the absence of such specificity in genetic mouse models of HD.